{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:27:32Z","timestamp":1762093652412,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006310","name":"Medicinska Forskningsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006310","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.bbrc.2010.10.052","type":"journal-article","created":{"date-parts":[[2010,10,26]],"date-time":"2010-10-26T04:35:25Z","timestamp":1288067725000},"page":"471-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Activation of VPAC1 receptors aggravates early atherosclerosis in hypercholesterolemic apolipoprotein E-deficient mice"],"prefix":"10.1016","volume":"402","author":[{"given":"Yuri","family":"Sheikine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Deodato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peder S","family":"Olofsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leif A","family":"S\u00f6derstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna M","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inger","family":"Bodin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats","family":"Rudling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvar","family":"Theodorsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6ran K","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2010.10.052_b0005","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1073\/pnas.74.8.3424","article-title":"Vasoactive intestinal polypeptide in brain: localization in and release from isolated nerve terminals","volume":"74","author":"Giachetti","year":"1977","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2010.10.052_b0010","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S0196-9781(98)00102-8","article-title":"Role of VIP PACAP, and related peptides in the regulation of the hypothalamo-pituitary-adrenal axis","volume":"19","author":"Nussdorfer","year":"1998","journal-title":"Peptides"},{"key":"10.1016\/j.bbrc.2010.10.052_b0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/pr.56.2.7","article-title":"The significance of vasoactive intestinal peptide in immunomodulation","volume":"56","author":"Delgado","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bbrc.2010.10.052_b0020","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0167-0115(02)00099-X","article-title":"Molecular pharmacology and structure of VPAC receptors for VIP and PACAP","volume":"108","author":"Laburthe","year":"2002","journal-title":"Regul. Pept."},{"key":"10.1016\/j.bbrc.2010.10.052_b0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0165-5728(96)00063-X","article-title":"Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes","volume":"68","author":"Delgado","year":"1996","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbrc.2010.10.052_b0030","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1196\/annals.1317.031","article-title":"VIP-PACAP system in immunity: new insights for multitarget therapy","volume":"1070","author":"Gomariz","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bbrc.2010.10.052_b0035","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/87887","article-title":"Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease","volume":"7","author":"Delgado","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2010.10.052_b0040","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1053\/gast.2003.50141","article-title":"Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn\u2019s disease","volume":"124","author":"Abad","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrc.2010.10.052_b0045","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2353\/ajpath.2006.051081","article-title":"Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses","volume":"168","author":"Gonzalez-Rey","year":"2006","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbrc.2010.10.052_b0050","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s10875-006-9042-2","article-title":"Vasoactive intestinal polypeptide suppressed experimental autoimmune encephalomyelitis by inhibiting T helper 1 responses","volume":"26","author":"Li","year":"2006","journal-title":"J. clin. immunol."},{"key":"10.1016\/j.bbrc.2010.10.052_b0055","first-page":"62","article-title":"VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production","volume":"30","author":"Kojima","year":"2005","journal-title":"Pancreas"},{"key":"10.1016\/j.bbrc.2010.10.052_b0060","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.pathol.1.110304.100100","article-title":"Inflammation and atherosclerosis","volume":"1","author":"Hansson","year":"2006","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.bbrc.2010.10.052_b0065","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1517\/14712598.4.4.599","article-title":"Immunomodulation and vaccination for atherosclerosis","volume":"4","author":"Zhou","year":"2004","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.bbrc.2010.10.052_b0070","first-page":"293","article-title":"Quantification of atherosclerosis in mice","volume":"209","author":"Daugherty","year":"2003","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bbrc.2010.10.052_b0075","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1172\/JCI119892","article-title":"Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice","volume":"102","author":"Nicoletti","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbrc.2010.10.052_b0080","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-2362.2006.01597.x","article-title":"Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system","volume":"36","author":"Parini","year":"2006","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.bbrc.2010.10.052_b0085","doi-asserted-by":"crossref","first-page":"24003","DOI":"10.1074\/jbc.M002325200","article-title":"Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide","volume":"275","author":"Nicole","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2010.10.052_b0090","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1113\/eph8702335","article-title":"Early myocardial fibrosis is associated with depletion of vasoactive intestinal peptide in rat heart","volume":"87","author":"Ye","year":"2002","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.bbrc.2010.10.052_b0095","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ejphar.2003.11.069","article-title":"Vasopeptidase inhibition reverses myocardial vasoactive intestinal peptide depletion and decreases fibrosis in salt sensitive hypertension","volume":"485","author":"Ye","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2010.10.052_b0100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00441-005-0001-7","article-title":"Down-regulation of vasoactive intestinal peptide and altered expression of its receptors in rat diabetic cardiomyopathy","volume":"323","author":"Dvorakova","year":"2006","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.bbrc.2010.10.052_b0105","first-page":"579","article-title":"The physiopathological role and prognostic value of the vasoactive intestinal peptide in acute myocardial infarct","volume":"40","author":"Lucia","year":"1995","journal-title":"Cardiologia"},{"key":"10.1016\/j.bbrc.2010.10.052_b0110","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1046\/j.1365-2265.2003.01913.x","article-title":"Vasoactive intestinal peptide (VIP): a new neuroendocrine marker of clinical progression in chronic heart failure?","volume":"59","author":"Lucia","year":"2003","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.bbrc.2010.10.052_b0115","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cellsig.2005.03.027","article-title":"The neuropeptide pituitary adenylate cyclase activating protein is a physiological activator of human monocytes","volume":"18","author":"El Zein","year":"2006","journal-title":"Cell Signal."},{"key":"10.1016\/j.bbrc.2010.10.052_b0120","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.4049\/jimmunol.173.6.4154","article-title":"Regulation of human polymorphonuclear leukocytes functions by the neuropeptide pituitary adenylate cyclase-activating polypeptide after activation of MAPKs","volume":"173","author":"Harfi","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbrc.2010.10.052_b0125","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/1381612013398374","article-title":"Immunology of VIP: a review and therapeutical perspectives","volume":"7","author":"Gomariz","year":"2001","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bbrc.2010.10.052_b0130","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1096\/fasebj.13.2.347","article-title":"Enhancement by vasoactive intestinal peptide of gamma-interferon production by antigen-stimulated type 1 helper T cells","volume":"13","author":"Jabrane-Ferrat","year":"1999","journal-title":"FASEB J."},{"key":"10.1016\/j.bbrc.2010.10.052_b0135","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1172\/JCI111934","article-title":"Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis","volume":"76","author":"Jonasson","year":"1985","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbrc.2010.10.052_b0140","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1161\/01.ATV.0000128849.12617.f4","article-title":"Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress","volume":"24","author":"Meir","year":"2004","journal-title":"Arterioscler., Thromb., Vasc. Biol."},{"key":"10.1016\/j.bbrc.2010.10.052_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7696(06)49001-X","article-title":"Endogenous ligands of PACAP\/VIP receptors in the autocrine-paracrine regulation of the adrenal gland","volume":"249","author":"Conconi","year":"2006","journal-title":"Int. Rev. Cytol."},{"key":"10.1016\/j.bbrc.2010.10.052_b0150","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejphar.2005.12.055","article-title":"Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors","volume":"533","author":"Groneberg","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2010.10.052_b0155","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/01.ATV.14.1.141","article-title":"Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression,","volume":"14","author":"Reddick","year":"1994","journal-title":"Arterioscler. Thromb."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X10019145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X10019145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:23:32Z","timestamp":1762093412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X10019145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0006291X10019145"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2010.10.052","relation":{},"ISSN":["0006-291X"],"issn-type":[{"type":"print","value":"0006-291X"}],"subject":[],"published":{"date-parts":[[2010,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activation of VPAC1 receptors aggravates early atherosclerosis in hypercholesterolemic apolipoprotein E-deficient mice","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2010.10.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}